NCT06580249 Efficacy and Mechanism of rTMS on the Symptoms of Pleasure Deficit in Adolescent Depression
| NCT ID | NCT06580249 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Depression |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2024-09-05 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2024-09-05 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
(1) Primary objective: to collect data on the score of pleasure deficit scale before and after repetitive transcranial magnetic stimulation treatment in adolescent depressed patients, and to verify its efficacy and safety in adolescent depressed patients in combination with the changes of clinical symptoms; (2) Secondary objective: to explore the relevant hemodynamic mechanisms in adolescent depressed patients before and after repetitive transcranial magnetic stimulation treatment.
Eligibility Criteria
Inclusion Criteria: 1. Age 10-19 years old (both 10 and 19), gender is not limited; 2. Meet the criteria for diagnosing MDD in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); 3. First episode or relapse, monophasic or bipolar depressive disorder; 4. No history of any form of antidepressant treatment (including medication, physical and psychotherapy) within 2 weeks prior to enrollment; 5. Habitual right-handedness; 6. Deficit of pleasure scale (DARS) \<22 points; 7. Score \>17 on the 17-item version of the Hamilton Depression Scale (HAMD-17); 8. After fully understanding the safety of rTMS, they were willing to actively cooperate with the treatment and signed an informed consent form. Exclusion Criteria: 1. Complicated with psychotic symptoms; 2. Comorbidity with major psychiatric disorders such as schizophrenia, delusional disorder, delirium, neurocognitive disorder, intellectual disability, and other mental disorders caused by other diseases; 3. History of primary neurologic disease or brain injury; 4. History of electroconvulsive therapy; 5. Contraindications to rTMS treatment, including cardiac pacemakers, neurostimulators, artificial metal heart valves, intracranial aneurysm clips, cochlear implants, and other types of metal implants (with the exception of oral supports);(6)History of epilepsy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06580249 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 19 Years, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06580249 currently recruiting?
Yes, NCT06580249 is actively recruiting participants. Contact the research team at matthewsiheng@outlook.com for enrollment information.
Where is the NCT06580249 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06580249 clinical trial?
NCT06580249 is sponsored by Xijing Hospital. The trial plans to enroll 44 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.